Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
$8.93
-$0.29(-2.36%)
At close: 4:00 PM EST
$8.93
-$0.29(-2.36%)
Day’s Range― - ―
52-Week Range$8.33 - $18.23
Previous CloseN/A
Volume96.76K
Average Volume (3M)1.09M
Market Cap
$315.35M
Enterprise Value$342.66M
Total Cash (Recent Filing)$88.91M
Total Debt (Recent Filing)$965.00K
Price to Earnings (P/E)1038.4
Beta1.69
Next Earnings
Mar 31, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding35,313,717
10 Day Avg. Volume1,019,346
30 Day Avg. Volume1,088,984
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)4.99
Price to Sales (P/S)9.23
P/FCF Ratio-17.84
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit4.99
Enterprise Value/Ebitda24.01
Forecast
1Y Price Target
$25.50Price Target Upside185.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.04
Revenue Forecast (FY)$85.76M
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsThe CHOPIN study demonstrated a substantial increase in 1-year Progression Free Survival (PFS), and a statistically significant increase in median PFS.
Financial PerformanceDelcath reported cash and cash equivalents of approximately $88.9M, which is believed to be sufficient to fund operations for the foreseeable future.
Market OpportunitiesDelcath estimates a combined $1.0B market opportunity for Hepzato in liver metastases due to colorectal and breast cancer, an attractive long-term growth opportunity.
Bears Say
Adverse EventsThe main challenge to widespread adoption of combination therapy is the high rates of Grade 3+ adverse events, though this is comparable to other safety outcomes.
Guidance ReductionDelcath issued preliminary 3Q25 financial results and lowered revenue guidance for FY2025.
Revenue DeclineRevenues declined by ~15% due to the HEPZATO’s participation in the NDRA program and unexpected summer seasonality that led to scheduling delays.
Delcath Systems News
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $8.33 and its highest was $18.23 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $315.35M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Mar 31, 2026 which is in 133 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Nov 04, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.024.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -0.08.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 35,313,717 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went down -4.622%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.50 (185.55% Upside)
$25.50 (185.55% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 17.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $98.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.25%
12-Months-Change
Fundamentals
Return on Equity
1.94%
Trailing 12-Months
Asset Growth
292.33%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. The company primarily operates in the oncology sector, specializing in its proprietary Chemosaturation Technology System (CTS), which is designed to deliver high-dose chemotherapy directly to tumors while minimizing systemic exposure. Delcath's core product offerings include the CTS for the treatment of liver cancers, particularly in patients with metastatic melanoma and other tumors that have spread to the liver.
DCTH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant advancements in clinical trials and revenue growth, but also highlighted challenges such as reduced revenue per kit and increased operating expenses impacting profitability.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$25.50
▲(185.55% Upside)
Technical Analysis
SurModics
―
ClearPoint Neuro
―
Senseonics Holdings
―
Nano-X Imaging
―
Treace Medical Concepts
―
Ownership Overview
30.88% Insiders
7.18% Mutual Funds
25.01% Other Institutional Investors
28.57% Public Companies and Individual Investors
Options Prices
Currently, No data available
---